261 related articles for article (PubMed ID: 32683996)
21. Organic acids as co-formers for co-amorphous systems - Influence of variation in molar ratio on the physicochemical properties of the co-amorphous systems.
Wu W; Ueda H; Löbmann K; Rades T; Grohganz H
Eur J Pharm Biopharm; 2018 Oct; 131():25-32. PubMed ID: 30040997
[TBL] [Abstract][Full Text] [Related]
22. Coamorphous Active Pharmaceutical Ingredient-Small Molecule Mixtures: Considerations in the Choice of Coformers for Enhancing Dissolution and Oral Bioavailability.
Newman A; Reutzel-Edens SM; Zografi G
J Pharm Sci; 2018 Jan; 107(1):5-17. PubMed ID: 28989014
[TBL] [Abstract][Full Text] [Related]
23. Amorphous systems for delivery of nutraceuticals: challenges opportunities.
Tomar D; Singh PK; Hoque S; Modani S; Sriram A; Kumar R; Madan J; Khatri D; Dua K
Crit Rev Food Sci Nutr; 2022; 62(5):1204-1221. PubMed ID: 33103462
[TBL] [Abstract][Full Text] [Related]
24. Solubilization of poorly water-soluble drugs using solid dispersions.
Tran TT; Tran PH; Khanh TN; Van TV; Lee BJ
Recent Pat Drug Deliv Formul; 2013 Aug; 7(2):122-33. PubMed ID: 23244679
[TBL] [Abstract][Full Text] [Related]
25. Application of hot melt extrusion for poorly water-soluble drugs: limitations, advances and future prospects.
Lu M; Guo Z; Li Y; Pang H; Lin L; Liu X; Pan X; Wu C
Curr Pharm Des; 2014; 20(3):369-87. PubMed ID: 23651401
[TBL] [Abstract][Full Text] [Related]
26. Application of melt extrusion in the development of a physically and chemically stable high-energy amorphous solid dispersion of a poorly water-soluble drug.
Lakshman JP; Cao Y; Kowalski J; Serajuddin AT
Mol Pharm; 2008; 5(6):994-1002. PubMed ID: 19434852
[TBL] [Abstract][Full Text] [Related]
27. Pharmaceutical solid dispersion technology: a strategy to improve dissolution of poorly water-soluble drugs.
Kumar S; Gupta SK
Recent Pat Drug Deliv Formul; 2013 Aug; 7(2):111-21. PubMed ID: 23331062
[TBL] [Abstract][Full Text] [Related]
28. Potentials of proniosomes for improving the oral bioavailability of poorly water-soluble drugs.
Song S; Tian B; Chen F; Zhang W; Pan Y; Zhang Q; Yang X; Pan W
Drug Dev Ind Pharm; 2015 Jan; 41(1):51-62. PubMed ID: 24111828
[TBL] [Abstract][Full Text] [Related]
29. Efflux Inhibitor Bicalutamide Increases Oral Bioavailability of the Poorly Soluble Efflux Substrate Docetaxel in Co-Amorphous Anti-Cancer Combination Therapy.
Bohr A; Nascimento TL; Harmankaya N; Weisser JJ; Wang Y; Grohganz H; Rades T; Löbmann K
Molecules; 2019 Jan; 24(2):. PubMed ID: 30642009
[TBL] [Abstract][Full Text] [Related]
30. Enhancing oral bioavailability of poorly soluble drugs with mesoporous silica based systems: opportunities and challenges.
Bremmell KE; Prestidge CA
Drug Dev Ind Pharm; 2019 Mar; 45(3):349-358. PubMed ID: 30411991
[TBL] [Abstract][Full Text] [Related]
31. Aspartame as a co-former in co-amorphous systems.
Wu W; Löbmann K; Schnitzkewitz J; Knuhtsen A; Pedersen DS; Grohganz H; Rades T
Int J Pharm; 2018 Oct; 549(1-2):380-387. PubMed ID: 30075253
[TBL] [Abstract][Full Text] [Related]
32. Current Trends in Self-Emulsifying Drug Delivery Systems (SEDDSs) to Enhance the Bioavailability of Poorly Water-Soluble Drugs.
Karwal R; Garg T; Rath G; Markandeywar TS
Crit Rev Ther Drug Carrier Syst; 2016; 33(1):1-39. PubMed ID: 27279337
[TBL] [Abstract][Full Text] [Related]
33. Supersaturating drug delivery systems: The potential of co-amorphous drug formulations.
Laitinen R; Löbmann K; Grohganz H; Priemel P; Strachan CJ; Rades T
Int J Pharm; 2017 Oct; 532(1):1-12. PubMed ID: 28870764
[TBL] [Abstract][Full Text] [Related]
34. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications.
Kawabata Y; Wada K; Nakatani M; Yamada S; Onoue S
Int J Pharm; 2011 Nov; 420(1):1-10. PubMed ID: 21884771
[TBL] [Abstract][Full Text] [Related]
35. Supercritical fluid particle design for poorly water-soluble drugs (review).
Sun Y
Curr Pharm Des; 2014; 20(3):349-68. PubMed ID: 23651403
[TBL] [Abstract][Full Text] [Related]
36. Nanocrystals Technology for Improving Bioavailability of Poorly Soluble Drugs: A Mini-Review.
Zhou Y; Du J; Wang L; Wang Y
J Nanosci Nanotechnol; 2017 Jan; 17(1):18-28. PubMed ID: 29616786
[TBL] [Abstract][Full Text] [Related]
37. Impact of polymer type on bioperformance and physical stability of hot melt extruded formulations of a poorly water soluble drug.
Mitra A; Li L; Marsac P; Marks B; Liu Z; Brown C
Int J Pharm; 2016 May; 505(1-2):107-14. PubMed ID: 27012984
[TBL] [Abstract][Full Text] [Related]
38. Solid dispersions: a strategy for poorly aqueous soluble drugs and technology updates.
Alam MA; Ali R; Al-Jenoobi FI; Al-Mohizea AM
Expert Opin Drug Deliv; 2012 Nov; 9(11):1419-40. PubMed ID: 23043303
[TBL] [Abstract][Full Text] [Related]
39. Microemulsions as drug delivery systems to improve the solubility and the bioavailability of poorly water-soluble drugs.
He CX; He ZG; Gao JQ
Expert Opin Drug Deliv; 2010 Apr; 7(4):445-60. PubMed ID: 20201713
[TBL] [Abstract][Full Text] [Related]
40. Drug delivery strategies for poorly water-soluble drugs: the industrial perspective.
van Hoogevest P; Liu X; Fahr A
Expert Opin Drug Deliv; 2011 Nov; 8(11):1481-500. PubMed ID: 21895540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
